ANOTHER SETBACK for hapless businessman David Stone, whose efforts to rescue one of his many companies has just fallen flat. For many, it is not Stone’s eclectic mix of investments that would be recognised but rather the headlines he made in 2023 as a result of his conviction for allowing the euthanasia drug pentobarbital to… Read more »
To access this content, you must be a Phoenix subscriber.
Get access to The Phoenix online for as low as €1.50 per week. Read all the regular online only Phoenix stories AND receive the packed digital edition every fortnight (25 per year). Great value for so many inside stories!